UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study

Charlie Song-Smith $^{a, 1}$, Edward Jacobs $^{b, c}$, James Rucker $^{d, e}$, Matthew Saint f , James Cooke g , & Marco Schlosser $^{h, i, 1}$

Marco Schlosser and James Cooke share last authorship.

Charlie Song-Smith,

Email: charlie.song-smith.19@ucl.ac.uk

UCL Medical School

University College London

London, United Kingdom

Marco Schlosser

Email: marco.schlosser@ucl.ac.uk

Division of Psychiatry

University College London

London, United Kingdom

Funding statement: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. James Rucker received salary support via the NIHR Clinician Scientist Fellowship Programme during the period of this research (CS-2017-17-007).

Competing interests statement: James Rucker has received payments for advisory work from Clerkenwell Health (Past), Beckley PsyTech (Past), Delica Therapeutics (Past), for articles written for Janssen, and financial assistance for attendance at conferences from Compass Pathways (past) and Janssen. James Rucker has received grant funding (received and managed by King's College London) from Compass Pathfinder, Beckley PsyTech, Multidisciplinary Association for Psychedelic Studies, National Institute for Health Research, Wellcome Trust, Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust. All other authors declare that they have no competing interests.

^a UCL Medical School, University College London, London, United Kingdom

^b Department of Psychiatry, University of Oxford, Oxford, United Kingdom

^c Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, United Kingdom

^d The Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

^e South London & Maudsley NHS Foundation Trust, Monks Orchard Road, Beckenham, Kent, United Kingdom

f University of Exeter Medical School, Exeter, UK

g Innerspace Institute, Portugal

^h Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom

ⁱ Institut für Psychotherapie Potsdam, Potsdam, Germany

¹ Corresponding authors: Charlie Song-Smith & Marco Schlosser

Abstract

Objective: To capture UK medical students' self-reported knowledge and harm assessment of psychedelics and to explore the factors associated with support for changing the legal status of psychedelics to facilitate further research.

Design: Cross-sectional, anonymous online survey of UK medical students using a non-random sampling method.

Setting: UK medical schools recognised by the General Medical Council.

Participants: The sample consisted of 132 medical students who had spent an average of 3.8 years (SD=1.4; range: 1 to 6) in medical school.

Results: Most students (83%) reported that they were aware of psychedelic research and only four participants (3%) said that they were not interested in learning more about this type of research. Although medical students' harm assessment of psychedelics closely aligned with that of experts, only 17% of students felt well-educated on psychedelic research. Teachings on psychedelics were only rarely encountered in their curriculum. Time spent at medical schools was not associated with more knowledge about psychedelics. On average, this sample of medical students showed strong support for changing the legal status of psychedelics to facilitate further research into their potential clinical applications. Regression modelling indicated that greater knowledge of psychedelics, lower estimated harm scores, more time spent in medical school, and lower perceived effectiveness of nonpharmacological mental health treatments were associated with a support for legal status change.

Conclusions: This is the first study to explore UK medical students' self-reported knowledge and attitudes towards psychedelics and their application in clinical research. Our findings reveal a significant interest among medical students to learn more about psychedelic research and a strong support for further psychedelic research. Future studies are needed to examine how medical education could be refined to adequately prepare medical students for a changing healthcare landscape in which psychedelic-assisted therapy could soon be implemented in clinical practice.

Keywords: Medical students, Psychedelics, Knowledge, Harm assessment, Medical education

Word count: 4618

Strengths and limitations of this study

- This study presents the first survey of UK medical students' attitudes towards psychedelics and their application in clinical research.
- The wide-ranging assessment included medical students' self-reported knowledge of
 psychedelics, a multidimensional harm assessment of psychedelics, level of support
 for changing the legal status of psychedelics to facilitate further research into their
 potential clinical applications, and students' perceptions of medical education on
 psychedelics and psychedelic research.
- The cross-sectional nature of our data prevented us from drawing causal conclusions about potential changes in students' attitudes and knowledge over time.
- The limited range of demographic variables did not allow for an in-depth characterisation of this sample and important predictors of attitudes might have been missed. Non-random sampling and selection bias could have impacted the generalisability of our findings as students already interested in drugs might have been more likely to participate.

Introduction

Since the early 1990s, there has been a steady resurgence of research involving psychedelics such as lysergic acid diethylamide (LSD), psilocybin, and N, N-Dimethyltryptamine (DMT) (1-3). After a short-lived period of medical use of psychedelics by clinicians and researchers in the middle of the 20th century, psychedelic research was effectively ended by prohibitive legislature in various countries (4). The clinical trials conducted prior to these legal sanctions suggested that psychedelics – which were frequently used in combination with or as an aid to psychotherapy – could positively impact a range of disorders, particularly mood disorders and alcohol dependence (5,6). These early findings have been corroborated by modern-era clinical trials, which support the therapeutic effects of psychedelics and psychedelic-assisted psychotherapy in some patient groups (for reviews see e.g., (7–9)). The largest published and ongoing psychedelic trials investigate the effects of psilocybin in combination with psychological support for the treatment of major depressive disorder (e.g., (10–14)). Clinical investigations into the therapeutic efficacy of related drugs, such as 3,4-Methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) (15,16) and ketamine for depression (17–19), have also advanced substantially. In the context of the present study, the term "psychedelic" will encompass the classic psychedelics (e.g., psilocybin, LSD) as well as MDMA and ketamine.

If current developments continue unhindered, some psychedelics and forms of psychedelic-assisted therapy will likely receive regulatory approval and thus transition from legally restricted use in research studies to integration in clinical practice (but see (20)). The extent to which psychedelics will be clinically implemented and disseminated will also depend on medical professionals' knowledge and attitudes towards these drugs. Despite the looming possibility of regulatory approval, research on medical professionals' opinions surrounding psychedelic and their use in clinical practice is in its infancy. A recent survey

indicated that US psychiatrists (n=106) largely believed in the therapeutic potential of psychedelics and were strongly in favour of federal funding to facilitate further research with these substances (21). Variables associated with a favourable assessment of psychedelics included greater psychedelic knowledge, fewer concerns about the drugs' addictive potential, and working in research. A prior survey study led by the same author had also suggested that psychiatrists (n=324) were supportive of further psychedelic research on mental health disorders, but the sample also tended to view these drugs as potentially dangerous and agreed with their restrictive scheduling for recreational use (22). A pilot study (n=83) of psychiatrists working in the UK's National Health Service (NHS) showed that most of them (77%) believed that controlled or therapeutic use of psychedelics should play a role in society (23). Notably, psychiatrists of all grades reported significant training needs and lacking preparedness or confidence to deliver psychedelic-assisted psychotherapy should it become available. Overall, most research conducted in this nascent field converges on the conclusion that a majority of psychiatrists and other mental health professionals – including psychologists and counsellors (24,25) – are supportive of further clinical research with psychedelics.

Given that tomorrow's psychiatrists are today's medical students, it is pertinent to consider medical students' knowledge and attitudes towards psychedelics. To date, only three studies on this topic have been published (26–28). In a sample of 213 US medical students, 83% and 52% of respondents believed that psilocybin should be legalised for recreational use and medical use, respectively (26). Students with greater self-reported knowledge of psilocybin and fewer concerns about potential negative effects reported more positive overall perceptions regarding the medical use of psilocybin. Another survey study of US medical students (n=132) suggested that almost all respondents (95%) believed that further research examining psychedelics' therapeutic potential is warranted (27). Overall, medical students

held positive attitudes toward psychedelics, but only 41% reported that they felt knowledgeable about psychedelics. None of the demographic variables, including age, sex, planned specialty (i.e., psychiatry, internal medicine etc.), and level of training, were associated with greater positive attitudes towards psychedelics. Lastly, another survey of US medical students (n=295) indicated that more favourable attitudes towards psychedelics were associated with a greater willingness to recommend psychedelic-assisted therapy to patients should it receive FDA approval (28). The present study aimed to further expand knowledge in this area by sampling the views and attitudes of medical students in the United Kingdom.

Using an anonymous online survey, we aimed to capture UK medical students' selfreported knowledge of psychedelics and their application in clinical research. We also aimed to compare medical students' harm assessment of psychoactive drugs with that of drug experts. We also aimed to examine to which extent participant characteristics were associated with support for changing the legal status of psychedelics to facilitate further research. Given the lack of empirical and theoretical work in this area, our hypotheses and statistical approaches should be viewed as primarily exploratory and our findings as preliminary. We expected more time spent in medical school to be associated with higher psychedelic knowledge and lower psychedelic harm composite scores. Regarding support for changing the legal status of psychedelics to facilitate further research, we expected students more knowledgeable of psychedelics to be more supportive of their legal status change; students assigning lower harm to psychedelics to be more supportive; more seasoned students to be more supportive; more psychiatrically interested students to be more supportive; students favourably assessing pharmacological and nonpharmacological to be more and less supportive, respectively; students more open to new experiences to be more supportive; and students with higher levels of neuroticism to be less supportive.

Methods

Procedures and survey design

This study used an anonymous online survey delivered via the Qualtrics web platform to collect cross-sectional data without recording participants' IP addresses. A short text asking individuals whether they would like to support research on medical students' knowledge and perceptions of common "recreational" drugs and their clinical uses was shared on UK university medical society mailing lists and bulletins, and social media platforms (LinkedIn, Twitter). To reduce self-selection bias, the study was advertised as a "Drugs and Mental Health" survey, rather than a survey about psychedelics. Interested individuals could follow a link to the study information sheet, which described the aims of the survey, the anonymous data collection, and the eligibility criteria (i.e. at least 18 years old, good understanding of the English language, currently enrolled in a UK medical programme accredited by the General Medical Council). Individuals were required to indicate their informed consent before starting the survey. The survey took approximately 10 minutes to complete and was accessible between October 2021 and March 2022. No financial or other incentives were offered for participation. This study received ethical approval from University College London's Research Ethics Committee (Project ID: 14309/007) and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments. All data was collected and processed in accordance with the 2018 UK General Data Protection Regulation. Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.

Participants

A total of 136 individuals consented to participate and completed the survey.

Incomplete responses were automatically deleted by Qualtrics. In the service of survey

quality control, we excluded four participants who took less than 5 minutes to complete the survey (i.e., the time it took to read through the survey at a fast pace without responding to any questions). The total sample thus consisted of medical 132 students without missing data.

Measures

To ensure anonymity, we collected only minimal demographic information including course year (i.e., years since starting training), participation in intercalated BSc or MBPhD programme, previous completion of university degree, and interest in pursuing a career in psychiatry.

To capture medical students' self-reported knowledge and the amount of education they had received on seven drugs (i.e, cannabis, cocaine, heroin, ketamine, LSD, magic mushrooms/psilocybin, ecstasy/MDMA), we used the following three statements:

- Self-reported knowledge: "Firstly, please indicate how well educated/knowledgeable
 you feel about these drugs. For example, this would include knowledge of
 pharmacology, physiology, subjective effects and adverse consequences of the drug."
- 2. Encountered in curriculum: "How often have you come across the drugs listed above in your teaching, including lectures, small group work and problem-based or selfdirected learning?"
- 3. Encountered in extracurricular reading: "How often have you come across these drugs in your own reading/research?"

The first statement used a sliding visual analogue scale (VAS) ranging from 0 ('no knowledge') to 100 ('excellent knowledge'), whilst the latter two questions used a VAS from 0 ('never') to 100 ('very often'). Commonly used non-psychedelic drugs were included to allow comparison of relative perceived harms, as well as to cover the fact that this was primarily a psychedelic survey. A psychedelic knowledge composite was computed by averaging the knowledge scores of LSD, psilocybin, MDMA, and ketamine (i.e., four scale

scores were combined), with higher composite scores indicating greater self-reported knowledge.

To measure medical students' perceptions of harms of the same seven drugs, the following six questions with a VAS from 0 (no harm) to 100 (severe harm) were used:

- 4. Drug-specific mortality: "How great is the potential of the drug to cause death by overdose (i.e., the intrinsic lethality)?"
- 5. Drug-related mortality: "To what extent is life shortened by the use of the drug, excluding deaths from overdose? For example, this could include deaths due to road traffic accidents, lung cancers, HIV and suicide."
- 6. Drug-specific damage: "How great is the damage to physical health (short of death) caused by the drug? For example, this could include liver damage, other organ damage, seizures, strokes."
- 7. Dependence: "To what extent does the drug cause addiction/dependence, i.e., the urge to continue to use despite adverse consequences?"
- 8. Drug-specific impairment of mental functioning: "To what extent does the drug cause acute mental health problems when taken?"
- 9. Drug-related impairment of mental functioning: "To what extent does the drug cause problems in the user's work or social life, leading to mental health problems (excluding addiction)?"

A psychedelic harm composite score was computed by averaging the harm scores of LSD, psilocybin, MDMA, and ketamine across the six harm assessment categories (i.e., 24 scale scores were combined), with higher composite scores indicating higher levels of harm. The harm-related questions were adopted from a cross-sectional survey (30) that utilised the 16 harm criteria introduced by a multidisciplinary panel of drug experts in a seminal paper on relative drug harms on behalf of the in the UK's Independent Scientific Committee on Drugs

(29). Using a brief survey to minimise attrition rate, we adopted only six of the 16 criteria covering physical harm (drug-specific mortality, drug-related mortality, drug-specific damage) and psychological harm (dependence, drug-specific impairment of mental functioning, drug-related impairment of mental functioning). Detailed information about these harm criteria can be found Nutt et al. (29).

To capture medical students' attitudes towards mental health treatments and research on psychedelics, we used the following questions and scales:

- 10. Perception of effectiveness of pharmacological (e.g., selective-serotonin reuptake inhibitors [SSRIs] and nonpharmacological treatments (e.g., psychotherapy): "Thinking about mental health conditions such as anxiety disorders, depression and addiction, how effective would you consider the following general treatment approaches for these conditions?" (VAS from 0 [not effective at all] to 100 [extremely effective])
- 11. Awareness of and interest in psychedelic research (adapted from the Psychedelic as Medicine Report, (31)): "Consider the following statement: 'Drugs such as psilocybin (the active ingredient in magic mushrooms) and MDMA (the active ingredient in ecstasy) have recently been investigated as potential treatments for mental health conditions such as depression, PTSD, and addiction.' Which of the following best describes your own awareness of this research area?" (5-point nominal scale: I am aware of this, and am well educated on the topic, I am aware of this, and curious to know more; I am aware of this, but it doesn't interest me; I am not aware of this, but am curious to know more; I am not aware of this, and it doesn't interest me).
- 12. Attitude towards changing legal status of psilocybin and MDMA: "Consider the following statement: 'Drugs that are considered to have no medical value and a high

risk of misuse or harm are listed in Schedule 1 of the UK Misuse of Drugs Regulations (2001); these currently include MDMA and psilocybin. Research involving schedule 1 drugs is associated with significantly increased costs, duration, and difficulty.' Given your current knowledge, to what extent would you support or oppose changing the legal status of these drugs to facilitate further research into their potential medical uses (while keeping restrictions on recreational use as they are)?" (VAS from 0 [strongly oppose] to 100 [strongly support])

A 'legal change' composite variable was created by averaging the psilocybin and MDMA legal change scores, with higher scores indicating greater support for changing the legal status to facilitate further research.

Another drug-related question asked medical students to rate, using a VAS from 0 (not important) to 100 (very important), the importance of the following factors in influencing their perception of the drugs included in this survey: my own and my friends' personal experiences; teaching as part of my course; media reporting; reading scientific papers/articles; a drug's legal class; advice from parents or other authority figures; general internet searches and online information.

To measure personality traits, the short version of the Big Five Inventory was used (32). This 10-item scale uses a 5-point Likert scale ranging from 1 (disagree strongly) to 5 (agree strongly) to capture openness to experience, conscientiousness, extraversion, agreeableness, and neuroticism (33). Each personality trait is captured by two items and total scores for each trait are computed by averaging the respective items scores. Higher subscale scores relate to higher trait levels. The 10-item version, despite being significantly shorter than the standard 44-item Big Five Inventory on which it is based, has retained good levels of reliability and validity (32).

Data analysis

Associations of drug-related measures with course year

The relationship between course year and drug-related measures was assessed using Pearson's correlation coefficients.

Regression analysis

We built the statistical models within a risk prediction framework using a stepwise backward elimination approach. The full mode considered the legal change composite score as the continuous outcome. Given the lack of research on medical students' attitudes towards psychedelic research that could guide the selection of potential predictors, we decided to include the following variables as continuous explanatory variables: psychedelic knowledge composite scores, psychedelic harm composite scores, course year, interest in psychiatry, perception of effectiveness of mental health treatments, openness to experience, and neuroticism. The explanatory variable associated with the highest p-value above 0.05 was then deleted. The model was then refitted without the deleted explanatory variable and the estimates and their associated p-values recomputed. The final prediction model thus retained explanatory variables if they were associated with p < 0.05. This threshold for inclusion was chosen to ensure model stability and reduce overfitting. Stata/MP version 16.0 and R version 4.0.2 were used for all analyses.

Data availability statement

All data and analysis scripts can be found on the senior author's Open Science Framework profile: https://osf.io/tmp3u/.

Results

Descriptive statistics

Participant characteristics for the total sample of 132 medical students are displayed in Table 1. Descriptive statistics of self-reported knowledge and the extent to which medical students had encountered a discussion of the listed drugs (i.e., cannabis, cocaine, heroin,

12

ketamine, LSD, psilocybin, MDMA) in their curriculum or during extracurricular reading and research are displayed in Table 2. Descriptive statistics on medical students' assessment of the harm caused by the listed drugs are reported in Table 3 and visually depicted in Figure 1.

The mean rating (on a scale from 0 [strongly oppose] to 100 [strongly support]) for the change in legal status for psilocybin was 80.2 (SD = 24.8) and for MDMA was 74.3 (SD = 27.7). Both distributions were left-skewed (i.e., more values are on the right side of the mean) with 59 (44.7%) and 50 (37.9%) medical students having a score of 100 for psilocybin and MDMA, respectively. The legal change composite score showed a similar divergence from normality (skewness: -0.98, kurtosis: 3.02).

The other two composite scores did not markedly diverge from normality as indicated by estimates of skewness (psychedelic knowledge: -0.17; psychedelic harm: -0.13) and kurtosis (psychedelic knowledge: 2.30; psychedelic harm: 2.34) and visual inspection of the histograms.

Associations of drug-related measures with course year

More course years were associated with lower psychedelic harm composite scores (Pearson's correlation coefficient r = -0.22, 95% CI: -0.05 to -0.38, p = 0.012). In contrast to our expectations, number of course years were not correlated with higher psychedelic knowledge composite scores (r = 0.12, 95% CI: -0.04 to 0.30, p = 0.129).

Regression analysis

Table 4 reports the results from the full model and the final prediction model. Using a stepwise backward elimination approach with significance threshold of p = 0.05, explanatory variables were removed in the following order: neuroticism, perception of pharmacological treatments, interest in psychiatry, and, in the last step, openness to experience. The final prediction model for legal change composite scores thus retained psychedelic knowledge composite scores, psychedelic harm composite scores, course year, and perception of the

effectiveness of nonpharmacological treatments (all unstandardised estimates are displayed in Table 4). In other words, in the final regression model, greater psychedelic knowledge and more course years were associated with greater support for legal change, whereas greater psychedelic harm scores and a more favourable perception of the effectiveness of nonpharmacological treatments were associated with weaker support for legal change of psychedelics. Assumptions for all regression models were met.

Discussion

The primary aim of this cross-sectional study was to capture UK medical students' self-reported knowledge and harm assessment of psychedelics and the degree to which they would support changing the legal status of psychedelic substances, particularly psilocybin and MDMA, to facilitate further research into their potential medical uses without changing restrictions on recreational use. Results indicated that 83% of medical students were aware of psychedelic research and only four participants said that they were not interested in learning more about this type of research. Medical students evaluated their own experience and that of their friends as the most important influence on their perception of drugs in general. Another important influence was their study of scientific articles, whereas media reporting and a drug's legal class had the least influence on their perception of drugs.

UK medical students were highly supportive of changing the legal status of psilocybin and MDMA, with 45% and 38% expressing the strongest possible support (i.e., a score of 100 on a scale from 0 [strongly oppose] to 100 [strongly support]) for psilocybin and MDMA, respectively. Relatedly, we aimed to explore the variables that would predict the extent to which medical students were in support of changing the legal status. Regression modelling suggested that students who reported greater knowledge of psychedelics, assigned lower harm scores to psychedelics, had spent more time spent in medical education, and assigned lower effectiveness scores to nonpharmacological mental health treatments showed

a greater support for legal status change. The contribution of these variables was in line with our prediction. However, diverging from our expectation was the absence of a relationship between support for legal change and an interest in psychiatry, the perceived effectiveness of pharmacological treatments, and the personality traits of openness to experience and neuroticism.

Although time spent in medical school itself was associated with lower harm ratings of psychedelics, it was not associated with greater self-reported knowledge of psychedelics, suggesting that medical degree curricula do not contain much teaching about psychedelics. This explanation also aligns with the low reported frequency with which medical students encountered the classic psychedelics, psilocybin and LSD, in their curriculum. An alternative explanation, for instance, that medical students attracted to a survey on drugs and mental health tend to have greater knowledge of psychedelics (resulting in ceiling effects), was not reflected in the data, which showed self-reported psychedelic knowledge to be approximately normally distributed.

Medical students' multidimensional harm assessment of seven drugs resulted in an order of assigned overall harm scores that closely matched the order that was assigned by drug expert in a widely-cited harm assessment report conducted on behalf of the UK's Independent Scientific Committee on Drugs (29). In alignment with the expert rating, medical students assigned the highest overall harm score to heroin and cocaine and the lowest to psilocybin. Differences emerged in relation to the rank order of cannabis, which experts rated as substantially more harmful than medical students. In contrast, medical students perceived MDMA to be the third most harmful substance amongst the list of seven drugs assessed in the present study, whereas experts judged the harm of MDMA to be similar to that of LSD and psilocybin.

Limitations

This study has important limitations that need to be considered when interpreting our results. First, the cross-sectional nature of our data prevents us from drawing causal conclusions about the association between support for changing the legal status of psychedelics and the potential predictors we have considered. Future research with larger sample sizes, more detailed demographic information, objective assessments of students' knowledge, and longitudinal follow-ups are needed to further understand how medical education shapes students' perception of psychedelics and the factors that influence the degree to which students' views align with empirical evidence and expert opinion. Second, some of the measures we applied were tailor-made for this survey and not previously validated. Our harm assessment was adapted from Nutt et al. (29), but we used only six of the 16 harm criteria these researchers proposed; and none of our harm criteria captured harm to others. We also did not include an assessment of other commonly used drugs, such as alcohol and tobacco, preventing us from drawing potentially insightful comparisons. The brevity of our assessment was to keep attrition rates as low as possible. Future research would benefit from a more in-depth and comprehensive assessment of UK medical students' views and attitudes surrounding psychedelics and their application in clinical research. Third, we relied on self-report data gathered via an anonymous online survey; we did not conduct an objective assessment of knowledge about psychedelics (e.g., a multiple choice test) and, therefore, cannot assess the validity and reliability of students' self-report. Lastly, generalisability of our study may be limited due to the present sample's high awareness of and interest in psychedelic research. Despite efforts to minimise selection bias by avoiding the term "psychedelic" during recruitment, it is likely that the students who completed the survey were not representative of the general UK medical student population.

Conclusion

This is the first study to explore UK medical students' self-reported knowledge and

perceptions of psychedelics. Medical students showed strong support for changing the legal

status of psychedelics to facilitate further research into their potential clinical applications. In

general, medical students only rarely encountered teachings on psychedelics in their medical

education. Whilst only a small percentage of medical students felt well-educated on

psychedelic research, a large majority were interested to learn more, likely reflecting the re-

emergence of clinical interest in this area.

Author contributions

Charlie Song-Smith: Conception of the work, Methodology, Data acquisition, Data analysis,

Reviewing the work critically for important intellectual content.

Edward Jacobs: Conception of the work, Methodology, Reviewing the work critically for

important intellectual content, Supervision.

James Rucker: Conception of the work, Reviewing the work critically for important

intellectual content.

Matthew Saint: Conception of the work, Reviewing the work critically for important

intellectual content.

James Cooke: Conception of the work, Methodology, Reviewing the work critically for

important intellectual content, Supervision.

Marco Schlosser: Writing of the original draft, Conception of the work, Methodology, Data

17

analysis, Data interpretation, Visualisation, Supervision.

Table 1. Demographics and participant characteristics (N = 132).

Variable	Mean (SD) or n (%)
Course years (i.e., time spent in medical education)	3.8 (1.4), range: 1 to 6
First year	6 (4.6%)
Second year	14 (10.6%)
Third year	40 (30.3%)
Fourth year	32 (24.2%)
Fifth year	17 (12.9%)
Sixth year	23 (17.4%)
Enrolled in or completed an intercalated degree	62 (47.0%)
Attained a previous university degree	29 (22.0%)
Interest in psychiatry	
I am confident I will pursue a career in psychiatry.	8 (6.1%)
I consider psychiatry one of my more likely career paths.	35 (26.5%)
I have not ruled out psychiatry, but it is not one of my more likely career paths.	39 (29.6%)
I consider psychiatry one of my less likely career paths.	35 (26.5%)
I am confident I will not pursue a career in psychiatry.	15 (11.4%)
Influence on perceptions of drugs (range: 0 [not important] to 100 [very important])	
My own and my friends' personal experiences	77 (20)
Teaching as part of my course	44 (29)
Media reporting	39 (26)
Reading scientific papers/articles	65 (28)
A drug's legal class	28 (29)
Advice from parents or other authority figures	34 (28)
General internet searches and online information	61 (24)
Awareness of and interest in psychedelic research	
I am aware of this, and am well educated on the topic.	22 (16.7%)
I am aware of this, and curious to know more.	84 (63.6%)
I am aware of this, but it doesn't interest me.	3 (2.3%)
I am not aware of this, but am curious to know more.	22 (16.7%)
I am not aware of this, and it doesn't interest me.	1 (0.8%)
Perception of mental health treatments (0 [not effective] to 100 [extremely effective])	
Pharmacological (e.g., selective-serotonin reuptake inhibitors [SSRIs])	58.7 (19.7)
Psychotherapy	66.9 (20.9)
Openness to experience (BFI-10)	3.72 (0.92)
Conscientiousness (BFI-10)	3.76 (0.88)
Extraversion (BFI-10)	3.61 (0.98)
Agreeableness (BFI-10)	3.63 (0.86)
Neuroticism (BFI-10)	3.01 (1.14)

Abbreviations: SD, standard deviation; BFI-10, 10-item Big Five Inventory.

Table 2. Descriptive statistics of medical students' self-reported knowledge and frequency of encountering psychedelics in teaching and in extracurricular reading (N = 132).

	Self-reported knowledge 1	Encountered in curriculum ²	Encountered in extracurricular
			reading ²
Cannabis	75.6 (17.7)	43.9 (28.4)	60.1 (26.5)
Cocaine	65.6 (22.2)	42.5 (27.5)	46.0 (28.4)
Heroin	60.2 (21.7)	39.5 (29.8)	41.3 (30.0)
Ketamine	61.2 (22.5)	32.2 (27.5)	41.9 (28.9)
LSD	56.1 (27.9)	16.8 (19.7)	39.8 (33.7)
Magic mushrooms	57.5 (29.7)	14.1 (19.9)	36.4 (33.0)
MDMA (ecstasy)	64.5 (23.4)	27.8 (25.5)	40.0 (31.1)

Note. All variables represent the mean (and standard deviation).

¹ Ranging from 0 (no knowledge) to 100 (excellent knowledge).

² Ranging from 0 (never) to 100 (very often).

Table 3. Multidimensional harm assessment of seven drugs (N = 132).

	Drug-specific	Drug-related	Drug-specific	Dependence	Drug-specific impairment of Drug-related impairment of	
	mortality	mortality	damage		mental functioning	mental functioning
Cannabis	13.3 (17.6)	38.2 (25.5)	34.9 (25.5)	48.5 (27.5)	58.4 (27.4)	48.9 (26.7)
Cocaine	70.8 (21.4)	66.4 (20.2)	73.5 (17.9)	80 (16.9)	64 (23.7)	68.4 (22.8)
Heroin	89.9 (14.3)	85.3 (16.9)	84.5 (15.7)	93.9 (11.9)	69.5 (25.5)	89.3 (13.8)
Ketamine	57.4 (27.7)	49.4 (25)	54.6 (24.8)	49.7 (25.8)	52.6 (25)	49.6 (24.9)
LSD	35.5 (28.7)	39.4 (28.1)	36.5 (28.9)	31.1 (26.5)	60.9 (26.1)	39.4 (27.3)
Magic mushrooms	28.1 (26.2)	32.3 (25.6)	29.4 (24.6)	27.2 (23.7)	55.2 (28)	36.5 (27.2)
MDMA (ecstasy)	63.5 (26.7)	53.7 (25.3)	55.9 (25.6)	48.1 (26.6)	59 (26.2)	48 (24.6)

Note. All values represent the mean (and 95% confidence interval) on a scale ranging from 0 (no harm) to 100 (severe harm).

Table 4. Multivariable linear regression models of the association with support for legal change (N = 132).

	Legal change composite scores ¹				
	Full model				
Explanatory variables (unstandardised)	Estimate	95% CI	<i>p</i> -value		
Psychedelic knowledge	0.31	0.13 to 0.48	0.001		
Psychedelic harm	-0.43	-0.66 to -0.21	< 0.001		
Course year (1 year)	2.82	0.16 to 5.48	0.038		
Interest in psychiatry	-0.68	-4.01 to 2.65	0.687		
Perception of pharmacological treatments	-0.01	-0.22 to 0.2	0.927		
Perception of nonpharmacological treatments	-0.19	-0.38 to 0	0.051		
Openness to experience	1.62	-2.4 to 5.64	0.426		
Neuroticism	-0.10	-3.35 to 3.16	0.952		
	Final prediction model				
Explanatory variables (unstandardised)	Estimate	95% CI	<i>p</i> -value		
Psychedelic knowledge	0.31	0.14 to 0.48	< 0.001		
Psychedelic harm	-0.45	-0.65 to -0.24	< 0.001		
Course year (1 year)	3.00	0.4 to 5.59	0.024		
Perception of nonpharmacological treatments	-0.18	-0.36 to 0	0.044		

Abbreviations: CI, confidence interval.

¹ Ranging from 0 (strongly oppose) to 100 (strongly support).

 $^{^{2}}$ The final model retained all explanatory variables with p < 0.05.

Figure 1. Drugs ordered by their overall harm scores, showing sub-scores for each of the six harm criteria. Harm scores range from 0 (no harm) to 100 (severe harm). DSM = drug-specific mortality. DRM = drug-related mortality. DSD = drug-specific damage. DEP = dependence. DSI = drug-specific impairment of mental functioning. DRI = drug-related impairment of mental functioning. LSD = lysergic acid diethylamide.

References

- 1. Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. 2017 Oct;42(11):2105–13.
- 2. Nichols DE. Psychedelics. Barker EL, editor. Pharmacol Rev. 2016 Apr 1;68(2):264–355.
- 3. Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic Psychiatry's Brave New World. Cell. 2020 Apr 2;181(1):24–8.
- 4. Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018 Nov 1;142:200–18.
- 5. Nichols DE, Walter H. The History of Psychedelics in Psychiatry. Pharmacopsychiatry. 2021 Jul;54(4):151–66.
- 6. Nichols D, Johnson M, Nichols C. Psychedelics as Medicines: An Emerging New Paradigm. Clin Pharmacol Ther. 2017;101(2):209–19.
- 7. Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand. 2021;143(2):101–18.
- 8. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020 May;177(5):391–410.
- 9. Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019 May 1;197:83–102.
- 10. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402–11.
- 11. Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023 Sep 5;330(9):843–53.
- 12. Rotz R von, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebocontrolled, double-blind, randomised clinical trial. eClinicalMedicine [Internet]. 2023 Feb 1 [cited 2023 Nov 29];56. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00538-7/fulltext?trk=public_post_reshare_feed-article-content
- 13. Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023 Apr 14;327:120–7.

- 14. Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, et al. Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. Neurosci Appl. 2022 Jan 1;1:100104.
- 15. Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebocontrolled phase 3 study. Nat Med. 2021 Jun;27(6):1025–33.
- 16. Illingworth BJ, Lewis DJ, Lambarth AT, Stocking K, Duffy JM, Jelen LA, et al. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis. J Psychopharmacol (Oxf). 2021 May 1;35(5):501–11.
- 17. aan het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for Depression: Where Do We Go from Here? Biol Psychiatry. 2012 Oct 1;72(7):537–47.
- 18. Meshkat S, Haikazian S, Di Vincenzo JD, Fancy F, Johnson D, Chen-Li D, et al. Oral ketamine for depression: An updated systematic review. World J Biol Psychiatry. 2023 Aug 9;24(7):545–57.
- 19. Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, et al. Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2016 Apr 1;19(4):pyv124.
- 20. Aday JS, Carhart-Harris RL, Woolley JD. Emerging Challenges for Psychedelic Therapy. JAMA Psychiatry. 2023 Jun 1;80(6):533–4.
- 21. Barnett BS, Beaussant Y, King F, Doblin R. Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey. J Psychoactive Drugs. 2022 May 27;54(3):269–77.
- 22. Barnett BS, Siu WO, Pope HGJ. A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens. J Nerv Ment Dis. 2018 Jun;206(6):476.
- Page LA, Rehman A, Syed H, Forcer K, Campbell G. The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy. Front Psychiatry [Internet]. 2021 [cited 2023 Nov 29];12. Available from: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.743599
- 24. Davis AK, Agin-Liebes G, España M, Pilecki B, Luoma J. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. J Psychoactive Drugs. 2022 Aug 8;54(4):309–18.
- 25. Hearn BG, Brubaker MD, Richardson G. Counselors' attitudes toward psychedelics and their use in therapy. J Couns Dev. 2022;100(4):364–73.
- Wang K, Sun Y, Nava B, Sampiere L, Jacobs RJ. Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice. Cureus. 2023;15(4):e37450.

- 27. Li I, Fong R, Hagen M, Tabaac B. Medical student attitudes and perceptions of psychedelic-assisted therapies. Front Psychiatry. 2023 Jun 27;14:1190507.
- 28. Pagán AF, Lex C, Soares JC, Meyer TD. Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter? Psychedelic Med. 2023 Sep;1(3):130–8.
- 29. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010 Nov 6;376(9752):1558–65.
- 30. Cheeta S, Halil A, Kenny M, Sheehan E, Zamyadi R, Williams AL, et al. Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people. BMJ Open. 2018 Nov 1;8(11):e021109.
- 31. Prohibition Partners. PSYCH: The Psychedelics as Medicine Report Second Edition. 2020.
- 32. Rammstedt B, John OP. Measuring personality in one minute or less: A 10-item short version of the Big Five Inventory in English and German. J Res Personal. 2007 Feb 1;41(1):203–12.
- 33. John OP, Srivastava S. The Big Five Trait taxonomy: History, measurement, and theoretical perspectives. In: Handbook of personality: Theory and research, 2nd ed. New York, NY, US: Guilford Press; 1999. p. 102–38.

